CA2948436A1 - Novel compounds useful as s100-inhibitors - Google Patents

Novel compounds useful as s100-inhibitors Download PDF

Info

Publication number
CA2948436A1
CA2948436A1 CA2948436A CA2948436A CA2948436A1 CA 2948436 A1 CA2948436 A1 CA 2948436A1 CA 2948436 A CA2948436 A CA 2948436A CA 2948436 A CA2948436 A CA 2948436A CA 2948436 A1 CA2948436 A1 CA 2948436A1
Authority
CA
Canada
Prior art keywords
oxo
tetraen
dodeca
trifluoromethyl
triazatricyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2948436A
Other languages
English (en)
French (fr)
Inventor
Ulf Wellmar
David LIBERG
Maria EKBLAD
Marie BAINBRIDGE
Stephen EAST
Jonathan Hargrave
Natacha Prevost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA2948436A1 publication Critical patent/CA2948436A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
CA2948436A 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors Abandoned CA2948436A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169757.3 2014-05-23
EP14169757 2014-05-23
PCT/EP2015/061468 WO2015177367A1 (en) 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
CA2948436A1 true CA2948436A1 (en) 2015-11-26

Family

ID=50774707

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2948436A Abandoned CA2948436A1 (en) 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors

Country Status (12)

Country Link
US (1) US9771372B2 (OSRAM)
EP (1) EP2991990B1 (OSRAM)
JP (1) JP6580074B2 (OSRAM)
KR (1) KR20170005868A (OSRAM)
CN (1) CN106414448B (OSRAM)
AU (1) AU2015261775B2 (OSRAM)
BR (1) BR112016024749A2 (OSRAM)
CA (1) CA2948436A1 (OSRAM)
EA (1) EA030604B1 (OSRAM)
ES (1) ES2620751T3 (OSRAM)
MX (1) MX2016014483A (OSRAM)
WO (1) WO2015177367A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019208290A1 (ja) 2018-04-27 2019-10-31 国立大学法人 岡山大学 抗ｓ１００ａ８／ａ９抗体とその用途
US11197908B2 (en) 2018-07-17 2021-12-14 The Board Of Trustees Of The University Of Arkansas Peptoids and methods for attenuating inflammatory response
AU2020376350B2 (en) 2019-10-30 2025-08-14 National University Corporation Okayama University Prophylactic and/or therapeutic agent for inflammatory pulmonary disease
WO2023209141A1 (en) 2022-04-29 2023-11-02 Westfälische Wilhelms-Universität Münster Benzo[d]imidazo[1,2-a]imidazoles and their use in diagnosis
WO2025132458A1 (en) 2023-12-18 2025-06-26 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
NZ523749A (en) 2000-07-26 2005-03-24 Smithkline Beecham P Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
AU2002245590B2 (en) 2001-03-05 2006-06-29 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
GB0117506D0 (en) 2001-07-18 2001-09-12 Bayer Ag Imidazopyridinones
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
CA2476594C (en) * 2002-03-05 2012-10-09 Transtech Pharma, Inc. Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
CA2663856A1 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Jak-2 modulators and methods of use
AU2008231384B2 (en) 2007-03-23 2011-09-15 Amgen Inc. Heterocyclic compounds and their use
EP1986009A1 (en) * 2007-04-26 2008-10-29 Active Biotech AB Screening method
BRPI0812521A2 (pt) 2007-06-13 2015-06-23 Glaxosmithkline Llc Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
MX2010008039A (es) * 2008-01-22 2010-08-10 Takeda Pharmaceutical Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos.
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
CN102414180A (zh) 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
ES2552514T3 (es) 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Compuestos bicíclicos de piperazina
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
ES2620751T3 (es) 2017-06-29
CN106414448B (zh) 2019-04-19
WO2015177367A1 (en) 2015-11-26
AU2015261775A1 (en) 2016-12-08
MX2016014483A (es) 2017-01-23
EP2991990A1 (en) 2016-03-09
US20170204098A1 (en) 2017-07-20
EA030604B1 (ru) 2018-08-31
EA201692405A1 (ru) 2017-06-30
US9771372B2 (en) 2017-09-26
CN106414448A (zh) 2017-02-15
AU2015261775B2 (en) 2019-07-11
JP6580074B2 (ja) 2019-09-25
HK1221463A1 (en) 2017-06-02
KR20170005868A (ko) 2017-01-16
BR112016024749A2 (pt) 2017-08-15
EP2991990B1 (en) 2017-02-01
JP2017516772A (ja) 2017-06-22

Similar Documents

Publication Publication Date Title
JP7321194B2 (ja) セレブロン（ｃｒｂｎ）に対するリガンド
JP6914257B2 (ja) Ｒｏｒ−ガンマのモジュレーター
CA2971872C (en) Mutant idh1 inhibitors useful for treating cancer
CN108290879B (zh) 用作irak抑制剂的杂芳基化合物及其用途
CA2971640C (en) Cot modulators and methods of use thereof
JP5099005B2 (ja) ヘテロ化合物
TW202200563A (zh) 喹喔啉酮衍生物作為kras g12c突變蛋白的不可逆抑制劑
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
WO2019193540A1 (en) Heteroaryl derivatives of formula (i) as atf4 inhibitors
KR20200089718A (ko) 인돌 화합물 및 이의 용도
CA3108791A1 (en) Indole and azaindole inhibitors of pad enzymes
CA3007025A1 (en) Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
CN113164475A (zh) Dyrk1a的大环抑制剂
CA2948436A1 (en) Novel compounds useful as s100-inhibitors
CA2968030A1 (en) Substituted bridged urea analogs as sirtuin modulators
US10385069B2 (en) Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors
JP2022531936A (ja) イミダゾ［１，２－ａ］ピリミジンの位置選択的合成
CN112574176A (zh) 一种杂芳基类化合物及其应用
WO2025181830A2 (en) Polyheterocyclic compounds as peptidyl arginine deiminase 4 (pad4) inhibitors
HK1221463B (en) Novel compounds useful as s100-inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123

FZDE Discontinued

Effective date: 20211123